Genomic Announces Executive Appointments
Most recently, Popovits served as as senior vice president, marketing and sales. She holds a B.A. in business from Michigan State University. Cole comes to Genomic in 2004
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XMost recently, Popovits served as as senior vice president, marketing and sales. She holds a B.A. in business from Michigan State University. Cole comes to Genomic in 2004
The final value of the MDS Pharma Services goodwill write-down, previously estimated to be in the range of $270 million to $370 million, is $320 million. Including the
Most recently serving as vice president of global sales and service and vice president of marketing and R&D. He has also held several senior marketing and product management
In his last position, he was a principal at a consulting firm he founded in 2002, providing high-level interim financial management and M&A services. Before that, Schmidt served
The company has also experienced a reorder rate of over 90%. “The promise of personalized medicine is quickly becoming a reality for patients with lung and colon cancer
“This is yet another important step in Rosetta Genomics’ commercialization efforts,” noted Ronen Tamir, Chief Commercialization Officer at Rosetta Genomics. “As Israel provided its citizens with health insurance
“Our second quarter results demonstrate the strength of our business model with its strong recurring revenue and cash flow,” stated Gioacchino De Chirico, president and chief executive officer.
“The Board of Directors and management team of IRIS International are grateful to Dick Williams for his valuable contributions during a period in which we have experienced very
“We are delighted and grateful to have the continuing support of GCIC,” said Jake Orville, president and chief executive of Prognostix. “GCIC’s first grant enabled Prognostix to make
The process has also included a review of the potential out-licensing of assets, asset divestiture, or liquidation of the company. Vasogen also reported that during this process it